Concurrent Training on Patients With Type-II DM Associated PAD.
Launched by ZIAUDDIN UNIVERSITY · Sep 7, 2023
Trial Information
Current as of November 10, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study is looking at whether doing a mix of cardio and strength exercises at the same time (concurrent training) is better than cardio-alone training (aerobic training) for people with Type 2 diabetes and a common leg condition called peripheral artery disease (PAD). The researchers will compare outcomes after 12 weeks of exercise. They’ll look at blood sugar control (HbA1c), blood flow in the legs (ankle-brachial index or ABI), how far a person can walk before leg symptoms stop them (functional capacity), and overall quality of life related to the disease.
Who can join? About 80 adults aged 40–50 with long-standing Type 2 diabetes, PAD with leg pain when walking, and a resting ABI below 0.9, plus a sedentary lifestyle. To be eligible, they should not smoke or need insulin, and they must not have certain serious health problems or recent major surgery. Participants are randomly assigned to either concurrent training (a mix of aerobic and resistance exercises) or aerobic training (just cardio), three supervised sessions per week for 12 weeks. The study is being conducted at Ziauddin University in Karachi, Pakistan, and results are not yet available. Participants will have safety monitoring during exercise, and outcomes are measured at the end of the 12 weeks.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age: 40 - 50 years
- • Type-II DM
- • Duration of DM: \> 10 years
- • Baseline HbA1C (\> 6.6%)
- • Intermittent claudication corresponding to Fontaine Stage IIa
- • PAD by an ABI scale; \< 0.9 at rest
- • Had \< 160 mmHg SBP and \< 105 mmHg DBP
- • Sedentary lifestyle by IPAQ-SF
- Exclusion Criteria:
- • Smokers
- • Insulin dependent individuals
- • Patients with Complicated cardiovascular disease that might limit their ability to - participate in the intervention period physically (e.g. unstable cardiopulmonary symptoms, ischemic heart failure, or chronic kidney disease) and cancer
- • Any major surgery or revascularization procedure within the previous 1 year
- • In case of a history of severe arthritis that may limit exercise performance
- • Diabetic foot (ulceration or gangrene)
- • Patients with stroke
- • BMI = \>30 classified by WHO-Asian as obesity class II
- • Unable to follow the intervention protocol or visit three times per week for exercise
- • Participation in any clinical trial during the past six months
- • Revocation to consent
About Ziauddin University
Ziauddin University is a prestigious academic institution located in Karachi, Pakistan, dedicated to advancing medical education, research, and healthcare. As a clinical trial sponsor, Ziauddin University actively engages in innovative research initiatives aimed at improving patient outcomes and contributing to the global body of medical knowledge. With a commitment to ethical standards and scientific rigor, the university collaborates with healthcare professionals, researchers, and regulatory bodies to conduct clinical trials that address critical health challenges. Through its multidisciplinary approach, Ziauddin University strives to foster a culture of research excellence and enhance the quality of healthcare services in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Karachi, Sindh, Pakistan
Patients applied
Trial Officials
Uroosa Amin, DPT
Principal Investigator
Ziauddin University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported